Abstract
The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis H37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks. These regimens were 15 mg of rifampin per kg alone (R), rifampin plus 25 mg of isoniazid per kg (RH), rifampin plus 150 mg of pyrazinamide per kg (RZ), or rifampin plus isoniazid and pyrazinamide (RHZ). The interval between the rifampin gavage and the gavage with the other drugs ranged from 10 to 45 min, so that interference with rifampin absorption did not occur. Mice were sacrificed at 11 and 20 weeks after the termination of chemotherapy, with each killing being preceded by 3 weeks of high-dose dihydrocortisone treatment. Entire spleens and lungs were cultured. The proportions of mice with positive spleens at either killing time were 74% of 43 mice treated with R, 63% of 41 mice treated with RH, 65% of 43 mice treated with RZ, and 53% of 45 mice treated with RHZ, a just significant (P = 0.04) trend for fewer positive spleens with increasing numbers of drugs in the regimen. However, no trend was found in the corresponding proportions of mice with positive spleens or lungs, which were 81, 63, 65, and 71% for mice treated with R, RH, RZ, and RHZ, respectively. Thus, in the Cornell model, R alone, RH, RZ, and RHZ all had similar efficacies.
Full Text
The Full Text of this article is available as a PDF (169.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acocella G., Bonollo L., Garimoldi M., Mainardi M., Tenconi L. T., Nicolis F. B. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972 Jan;13(1):47–53. doi: 10.1136/gut.13.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Eur J Clin Pharmacol. 1974;7(3):217–225. doi: 10.1007/BF00560384. [DOI] [PubMed] [Google Scholar]
- Dickinson J. M., Aber V. R., Mitchison D. A. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis. 1977 Oct;116(4):627–635. doi: 10.1164/arrd.1977.116.4.627. [DOI] [PubMed] [Google Scholar]
- Dickinson J., Guy A., Mitchison D. A. Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother. 1992 Sep;36(9):2066–2067. doi: 10.1128/aac.36.9.2066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grosset J., Truffot-Pernot C., Lacroix C., Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother. 1992 Mar;36(3):548–551. doi: 10.1128/aac.36.3.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guy A., Dickinson J. M., Mitchison D. A. Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis. Tuber Lung Dis. 1993 Oct;74(5):310–316. doi: 10.1016/0962-8479(93)90105-7. [DOI] [PubMed] [Google Scholar]
- Iseman M. D. Less is more: short-course preventive therapy of tuberculosis. Am Rev Respir Dis. 1989 Nov;140(5):1187–1187. doi: 10.1164/ajrccm/140.5.1187. [DOI] [PubMed] [Google Scholar]
- Israili Z. H., Rogers C. M., el-Attar H. Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol. 1987 Jan;27(1):78–83. doi: 10.1177/009127008702700113. [DOI] [PubMed] [Google Scholar]
- Jain A., Mehta V. L., Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis. 1993 Apr;74(2):87–90. doi: 10.1016/0962-8479(93)90032-S. [DOI] [PubMed] [Google Scholar]
- Lecoeur H. F., Truffot-Pernot C., Grosset J. H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989 Nov;140(5):1189–1193. doi: 10.1164/ajrccm/140.5.1189. [DOI] [PubMed] [Google Scholar]
- MCCUNE R. M., Jr, MCDERMOTT W., TOMPSETT R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med. 1956 Nov 1;104(5):763–802. doi: 10.1084/jem.104.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchison D. A., Allen B. W., Carrol L., Dickinson J. M., Aber V. R. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol. 1972 May;5(2):165–175. doi: 10.1099/00222615-5-2-165. [DOI] [PubMed] [Google Scholar]
- Mitchison D. A. Pyrazinamide in the chemoprophylaxis of tuberculosis. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1467–1467. doi: 10.1164/ajrccm/142.6_Pt_1.1467. [DOI] [PubMed] [Google Scholar]
- REES R. J., HART P. D. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol. 1961 Feb;42:83–88. [PMC free article] [PubMed] [Google Scholar]
- WALLACE J. G. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis. 1961 Jun;83:866–871. doi: 10.1164/arrd.1961.83.6.866. [DOI] [PubMed] [Google Scholar]